AR019308A1 - Formulaciones de particulas novedosas. - Google Patents

Formulaciones de particulas novedosas.

Info

Publication number
AR019308A1
AR019308A1 ARP990102392A ARP990102392A AR019308A1 AR 019308 A1 AR019308 A1 AR 019308A1 AR P990102392 A ARP990102392 A AR P990102392A AR P990102392 A ARP990102392 A AR P990102392A AR 019308 A1 AR019308 A1 AR 019308A1
Authority
AR
Argentina
Prior art keywords
formulations
novelties
new
compounds
animals
Prior art date
Application number
ARP990102392A
Other languages
English (en)
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Publication of AR019308A1 publication Critical patent/AR019308A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invencion provee vehículos capaces de suministrar concentraciones elevadas de compuestos pobremente hidrofílicos/pobremente lipofílicos a animales,mediante la combinacion de compuestos que poseen dominios hidrofobicos biocompatibles con conjugados que poseen regiones tanto hidrofobicas como hidrofílicas.Dichas formulaciones son adecuadas para una cantidad de usos en animales, particularmente la administracion a los mismos de altas concentraciones de compuestosterapéuticamente utiles, sin unnivel indebido de efectos colaterales.
ARP990102392A 1998-05-20 1999-05-19 Formulaciones de particulas novedosas. AR019308A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8610898P 1998-05-20 1998-05-20

Publications (1)

Publication Number Publication Date
AR019308A1 true AR019308A1 (es) 2002-02-13

Family

ID=22196324

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102392A AR019308A1 (es) 1998-05-20 1999-05-19 Formulaciones de particulas novedosas.

Country Status (18)

Country Link
US (1) US6500461B2 (es)
EP (1) EP1079812A4 (es)
JP (1) JP2002535242A (es)
KR (1) KR20010052368A (es)
CN (1) CN1310612A (es)
AR (1) AR019308A1 (es)
AU (1) AU745015B2 (es)
BR (1) BR9911031A (es)
CA (1) CA2332545A1 (es)
EA (1) EA200001109A1 (es)
EE (1) EE200000693A (es)
ID (1) ID28166A (es)
IL (1) IL139541A0 (es)
NO (1) NO20005832L (es)
PL (1) PL344327A1 (es)
SK (1) SK17422000A3 (es)
TR (1) TR200003435T2 (es)
WO (1) WO1999059550A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US7608579B2 (en) 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US20050281799A1 (en) 2004-06-16 2005-12-22 Glen Gong Targeting damaged lung tissue using compositions
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US7553810B2 (en) 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
EP1781182B1 (en) 2004-07-08 2019-11-13 PneumRx, Inc. Pleural effusion treatment device
EP1786443B1 (en) 2004-07-19 2018-06-06 Celator Pharmaceuticals, Inc. Particulate constructs for release of active agents
BRPI0600285C1 (pt) * 2006-01-13 2011-10-11 Brz Biotecnologia Ltda compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
US20090136937A1 (en) 2007-05-09 2009-05-28 Coleman Matthew A Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
WO2009015037A2 (en) 2007-07-21 2009-01-29 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles
EP2209420A4 (en) 2007-10-09 2014-01-22 Univ St Louis IMAGING PARTICLES
US9468607B2 (en) 2007-10-09 2016-10-18 Washington University Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
EP2628727A3 (en) 2007-11-21 2013-12-25 Decode Genetics EHF Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders
AU2009204048B2 (en) 2008-01-11 2013-08-01 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as MCH antagonists
JP5539993B2 (ja) * 2008-09-23 2014-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 薬物送達のためのナノ担体
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
RU2506266C2 (ru) 2009-01-26 2014-02-10 Израэл Инститьют Фо Байолоджикал Рисерч Бициклические гетероциклические спиросоединения
CN101670095B (zh) * 2009-04-13 2012-05-23 北京大学 一种用于栓塞治疗的药物组合物及其制备方法
KR20120104512A (ko) 2009-07-14 2012-09-21 알바니 몰레큘라 리써치, 인크. 5-ｈｔ3 수용체 조절체, 이의 제조 방법, 및 그의 용도
US9808500B2 (en) 2009-12-17 2017-11-07 Washington University Antithrombotic nanoparticle
US9764043B2 (en) 2009-12-17 2017-09-19 Washington University Antithrombotic nanoparticle
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
AU2011239414A1 (en) 2010-04-15 2012-11-08 The Washington University Prodrug compositions, prodrug nanoparticles, and methods of use thereof
WO2011139899A2 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
US8895055B2 (en) 2011-12-21 2014-11-25 The Regents Of The University Of California Telodendrimer nanodiscs without apolipoprotein
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US9642916B2 (en) 2012-12-12 2017-05-09 The Regents Of The University Of California Porphyrin modified telodendrimers
WO2017044899A1 (en) 2015-09-11 2017-03-16 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
WO2018053316A1 (en) 2016-09-15 2018-03-22 The Regents Of The University Of California Improved hybrid telodendrimers
WO2018204421A2 (en) 2017-05-02 2018-11-08 Lawrence Livermore National Security, Llc Momp telonanoparticles, and related compositions, methods and systems
JP2021518413A (ja) 2018-03-20 2021-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害剤化合物及び組成物ならびに使用方法
EP3906233B1 (en) 2018-12-31 2024-01-31 Icahn School of Medicine at Mount Sinai Kinase inhibitor compounds and compositions and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
MX9203504A (es) * 1988-04-20 1992-07-01 Liposome Co Inc Complejo agente: lipido activo de alta proporcion.
JP2687448B2 (ja) * 1988-06-22 1997-12-08 大正製薬株式会社 イブプロフェン徐放性製剤
JPH0429924A (ja) * 1990-05-28 1992-01-31 Terumo Corp 脂溶性薬物含有注射用製剤
CA2085342A1 (en) 1990-06-14 1991-12-15 Milton R. Kaplan Stable aqueous drug suspensions
US5599556A (en) * 1991-12-31 1997-02-04 Abbott Laboratories Prolamine coatings for taste masking
CA2141582C (en) 1992-08-05 2003-09-30 Angelo Mario Morella Pelletised pharmaceutical composition
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5776486A (en) * 1993-05-28 1998-07-07 Aphios Corporation Methods and apparatus for making liposomes containing hydrophobic drugs
US5478860A (en) 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
DK0902783T3 (da) * 1995-09-12 2002-07-22 Liposome Co Inc Hydrolysefremmende, hydrofobe taxanderivater
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same

Also Published As

Publication number Publication date
JP2002535242A (ja) 2002-10-22
AU745015B2 (en) 2002-03-07
ID28166A (id) 2001-05-10
CN1310612A (zh) 2001-08-29
TR200003435T2 (tr) 2001-03-21
EP1079812A1 (en) 2001-03-07
NO20005832L (no) 2001-01-18
SK17422000A3 (sk) 2001-09-11
NO20005832D0 (no) 2000-11-17
PL344327A1 (en) 2001-10-22
BR9911031A (pt) 2002-01-29
WO1999059550A1 (en) 1999-11-25
US20020034536A1 (en) 2002-03-21
US6500461B2 (en) 2002-12-31
EA200001109A1 (ru) 2001-06-25
IL139541A0 (en) 2004-02-08
CA2332545A1 (en) 1999-11-25
AU4190699A (en) 1999-12-06
EE200000693A (et) 2002-04-15
EP1079812A4 (en) 2001-12-12
KR20010052368A (ko) 2001-06-25

Similar Documents

Publication Publication Date Title
AR019308A1 (es) Formulaciones de particulas novedosas.
BR0109272A (pt) Agentes conjugados terapêuticos de ácido poliglutâmico, métodos para suas preparações e usos
CY1109286T1 (el) Σκευασμα τυπου φυραματος που περιλαμβανουν διοξειδιο πυριτιου
BRPI0412975A (pt) espuma penetrante para uso farmacêutico
AU7522601A (en) Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
SV1999000016A (es) Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv
ES2138271T3 (es) Compuestos de 6-dimetil-amino-metil-1-fenil-ciclohexano como principio activo farmaceutico.
HUP0201425A2 (hu) Liposzómában alkalmazható, könnyen hasadó kötést tartalmazó konjugátum
ES2195189T3 (es) Benzonaftiridinas como agentes terapeuticos bronquiales.
AR015360A1 (es) Proceso para la manufactura de una composicion farmaceutica para reducir o prevenir los efectos de la inflamacion; dicha composicion farmaceutica y unelemento para aplicar la composicion farmaceutica en dicho proceso
GT200100037A (es) Las 5-alquilpirido (2,3-d) pirimidinas son inhibidoras de las cinasas de tirosina y que depende de la ciclina.
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
ATE347378T1 (de) Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung
ATE482723T1 (de) Halbfeste mukoadhäsive formulierungen
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
DK0839026T3 (da) Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
AR032293A1 (es) Estuche farmaceutico
CR7059A (es) USO DE AGONISTAS INVERSOS DE GABAa EN COMBINACION CON AGONISTAS PARCIALES DEL RECEPTOR DE NICOTINA, ESTROGENOS, MODULADORES SELECTIVOS DE ESTROGENOS O VITAMINA E PARA EL TRAMIENTO DE TRASTORNOS COGNITIVOS
ES2190082T3 (es) Concentrados estables de vitamina c.
AR021750A1 (es) Aparato para el tratamiento topico localizado de una enfermedad
ES2171691T3 (es) Derivados de la colchicina, uso de los mismos y formulaciones que los contienen.
HN1998000144A (es) Formulacion medicamentosa con liberacion controlada de sustancia activa.
PE20030973A1 (es) Cuerpos de inclusion que transportan glicerol-fosfato aceptables para uso farmaceutico
DK0930077T3 (da) Cyclodextrinpræparater indeholdende et avermectin- eller milbemycinderivat